Nasal Drug Delivery Technology Market Analysis 2026

MARKET DYNAMICS

Key Drivers

• Increasing prevalence of chronic respiratory diseases and allergies worldwide is driving demand for the nasal drug delivery technology market 

The increasing incidence of chronic respiratory disorders and allergies around the world is a major driver of growth in the Nasal Drug Delivery Technology Market. Millions of people worldwide suffer from conditions like asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and sinusitis, demanding effective and convenient treatment alternatives. Nasal drug delivery technology has various advantages for the treatment of these illnesses, including concentrated delivery of medication to the respiratory tract, a faster onset of action, and fewer systemic side effects than oral drugs. As the incidence of respiratory disorders rises due to causes such as urbanization, air pollution, and changing lifestyles, there is an increasing demand for innovative nasal drug delivery systems to fulfil patients' unmet medical needs. For instance, according to World Health Organisation reports, Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, with 3.23 million deaths in 2019. Low- and middle-income countries account for 90% of COPD fatalities among people under 70. Tobacco smoking causes over 70% of COPD cases in high-income countries, while household air pollution is a significant risk factor in low- and middle-income countries.
(SourceL:https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd))
Furthermore, nasal drug delivery technology has benefits such as improved drug absorption, higher patient compliance, and the ability to self-administer, making it a popular alternative for a variety of therapeutic applications. As healthcare systems attempt to improve patient outcomes and treatment quality, the Nasal Drug Delivery Technology Market is expected to grow further, driven by rising demand for effective and patient-friendly drug delivery technologies.

Key Restrain

• The limited drug absorption and shorter residence time may hamper the growth of the Nasal Drug Delivery Technology market 

The problem of achieving regular and accurate drug absorption through the nasal mucosa is a significant market limitation. Individual differences in nasal anatomy, mucociliary clearance mechanisms, and nasal congestion can all have an impact on the bioavailability and efficacy of nasal medicines. Furthermore, concerns with patient compliance, such as incorrect administration technique or inadequate dose, might have an impact on the effectiveness of nasal medication delivery. These complications in medication absorption and administration present challenges for manufacturers and healthcare practitioners, raising concerns regarding the dependability and predictability of nasal drug delivery technology. 

Key Opportunities

• Rising adoption of smart inhalers will create lucrative opportunities for the nasal drug delivery technology market

To ensure device actuation, asthma and COPD patients need to use an inhaler with skill and expertise. Device specialists, taking into account the patient's wants and demands, are attempting to adopt simple technologies for monitoring patients' dose accuracy and ease of use. Connected or smart devices for asthma and COPD are becoming more widely available, and they have proven effective in tracking and monitoring patients' illness status. For instance, in November 2019, Lupin introduced the ADHERO, a linked smart device for metered dose inhalers. Adhero, a reusable smart device using Bluetooth technology, can be mounted to the top of MDI. Smart devices with Bluetooth technology detect inhaler use and remind patients to take their prescriptions. As a result, such gadgets boost adherence to asthma therapies and help maintain their condition. Additionally, these devices provide precise information and are easy to use.
(Source:https://www.lupin.com/lupin-launches-adhero-first-of-its-kind-connected-smart-device-in-india-to-support-treatment-of-respiratory-disease/)

Impact of COVID-19 on the Nasal Drug Delivery Technology Market

The COVID-19 pandemic had a positive effect on the nasal drug delivery systems industry since many patients wanted to complete their chronic respiratory illness medication at home. As a result, inhalers were more commonly utilised at home than in hospitals or outpatient clinics. Nasal inhalers are increasingly widely used to treat asthma, migraines, and other mental illnesses. Additionally, a number of pharmaceutical companies have been interested in the development of vaccines that use nasal drug delivery technology, with several of them currently undergoing clinical studies. Furthermore, health officials encourage immunization, and the 200 billion doses of flu vaccine delivered last year represented a significant increase from previous years. Last year, manufacturers supplied a record number of 175 billion doses. This has resulted in the positive impact of the Covid-19 pandemic on the growth of the market. For instance, on February 9, 2022, Glenmark Pharmaceuticals Limited, a global pharmaceutical company, and SaNOtize Research & Development Corp., a Canadian pharmaceutical company, announced the launch of their Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adult COVID-19 patients at high risk of disease progression.
(Source:https://www.pharmaceutical-technology.com/news/glenmark-nasal-spray-covid-india/)
 

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Global Nasal Drug Delivery Technology Market is witnessing significant growth in the near future.

In 2023, the Sprays segment accounted for noticeable share of global Nasal Drug Delivery Technology Market and is projected to experience significant growth in the near future.

The Pressurized containers and Non-Pressurized containers segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies • GlaxoSmithKline PLC , Inc. and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.

Frequently Asked Questions (FAQs)